On November 26, 2025, updates regarding a new clinical trial titled “Efficacy of Therapeutic Percutaneous Electrolysis vs Laser Therapy in Supraspinatus Tendinopathy” were announced. Sponsored by Universidad Pontificia de Salamanca, the study aims to compare the outcomes of two distinct medical approaches. This trial could impact therapeutic interventions for individuals suffering from supraspinatus tendinopathy.
The trial, currently listed as “Not yet recruiting,” will analyze treatments involving electrolysis percutaneus and laser therapy for tendinopathy. As such, clinical teams working in rehabilitation and device regulation should monitor this study closely. The findings could influence therapeutic decisions and medical device advancements.
Below, find key sections to navigate this article conveniently:
- What are the trial details?
- Why is this study significant?
- Frequently Asked Questions
- Conclusion
- Disclaimer
- Announcement Line
What are the trial details?
The study involves two interventions:
- Device: Electrolysis percutaneus – A minimally invasive therapy using electrical currents to target the affected tendon.
- Device: Laser therapy – A therapeutic approach using concentrated light to address pain and inflammation.
The research team intends to evaluate the comparative efficacy of these technologies in improving tendon function and patient outcomes.
Why is this study significant?
Supraspinatus tendinopathy impacts many patients, leading to pain and reduced mobility. Innovations in therapeutic devices offer hope for better management of this condition.
This trial could influence device manufacturers, regulatory decision-makers, and clinicians. Key regulatory frameworks, such as Medical Device Regulation (MDR) Annex XIV, may find applications through the safety and performance data derived from this research.
Additionally, the treatment modalities could widen the scope of non-surgical interventions for musculoskeletal disorders.
Frequently Asked Questions
-
1. What is a clinical status of the trial?
It is classified as “Not yet recruiting.” Further updates will likely follow.
-
2. How do the two interventions differ?
Electrolysis percutaneus utilizes electrical stimulation, while laser therapy employs light modulation to address tendinopathy symptoms.
-
3. Who might benefit from findings?
Patients, clinicians, and medical device developers interested in non-invasive therapies for tendinopathy.
Conclusion
This clinical trial marks a pivotal opportunity to evaluate electrolysis percutaneus and laser therapy’s impact on supraspinatus tendinopathy. As details develop, regulatory professionals and clinicians should harness this data for advancing standards in treatment efficacy and device approvals.
Disclaimer
This article is informational only and does not constitute legal or regulatory advice. Always consult appropriate professionals for specific guidance.
Announcement Line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07247825?term=medical+device